BerandaARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$6,49
Setelah Jam Perdagangan Normal:(0,00%)0,00
$6,49
Tutup: 1 Des, 16.46.32 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$6,79
Rentang hari
$6,35 - $6,75
Rentang tahun
$5,86 - $24,14
Kapitalisasi pasar
184,40 jt USD
Volume Rata-Rata
1,81 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 17,15 jt | -58,84% |
Biaya operasional | 30,32 jt | -36,85% |
Penghasilan bersih | -13,45 jt | -94,81% |
Margin laba bersih | -78,41 | -373,49% |
Penghasilan per saham | -0,49 | -88,46% |
EBITDA | -15,75 jt | -60,30% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 180,36 jt | -23,96% |
Total aset | 282,34 jt | -23,83% |
Total liabilitas | 57,78 jt | -46,88% |
Total ekuitas | 224,56 jt | — |
Saham yang beredar | 28,41 jt | — |
Harga terhadap nilai buku | 0,82 | — |
Tingkat pengembalian aset | -13,95% | — |
Tingkat pengembalian modal | -16,23% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -13,45 jt | -94,81% |
Kas dari operasi | -17,15 jt | 27,83% |
Kas dari investasi | -181,00 rb | -126,25% |
Kas dari pembiayaan | 1,22 jt | 76,77% |
Perubahan kas bersih | -16,11 jt | 30,43% |
Arus kas bebas | -9,72 jt | 61,31% |
Tentang
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Didirikan
2013
Situs
Karyawan
175
